{"entity":{"id":"moma-341","kind":"drug","name":"MOMA-341","aka":[],"tldr":"MOMA-341 is an experimental small molecule from MOMA Therapeutics, in phase 1 trials for MSI-high / dMMR solid tumours, colorectal cancer and gastric cancer and other cancers.","summary":"MOMA-341 is a small molecule (oral, covalent) from MOMA Therapeutics. An oral, potent and selective covalent inhibitor of Werner (WRN) helicase, which MSI-high and mismatch repair deficient tumour cells need to survive; tested alone and with irinotecan or immunotherapy. Its furthest stage is phase 1, for MSI-high / dMMR solid tumours, colorectal cancer, gastric cancer and endometrial cancer. ClinicalTrials.gov registers it in one study linked below. NCT06974110 recruiting (registry, checked 3 Nov 2026); first patient dosed July 2025. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"MOMA Therapeutics: momatx.com","url":"https://momatx.com/posts/moma-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-for-moma-341/"},{"label":"MOMA Therapeutics: momatx.com","url":"https://momatx.com/posts/moma-therapeutics-announces-initiation-of-phase-1-clinical-trial-for-moma-313/"},{"label":"ClinicalTrials.gov: trials of MOMA-341","url":"https://clinicaltrials.gov/search?intr=MOMA-341"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","colorectal","gastric","endometrial"],"sections":[],"technologies":[],"targets":["wrn"],"drugs":[],"companies":["moma-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06974110"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"MOMA-341","modality":"Small molecule (oral, covalent)","mechanism":"An oral, potent and selective covalent inhibitor of Werner (WRN) helicase, which MSI-high and mismatch repair deficient tumour cells need to survive; tested alone and with irinotecan or immunotherapy.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/moma-341/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"wrn","kind":"target","name":"WRN helicase (MSI-high cancers)","route":"/targets/wrn/"}],"company":[{"id":"moma-therapeutics","kind":"company","name":"MOMA Therapeutics","route":"/companies/moma-therapeutics/"}],"trial":[{"id":"nct06974110","kind":"trial","name":"Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors","route":"/trials/nct06974110/"}]}}